Bristol Myers Squibb Fades on Latest Figures

Bristol Myers Squibb (NYSE: BMY) shares dipped Thursday, after the drug maker reported first-quarter revenue that topped expectations as its blockbuster blood thinner Eliquis and several new drugs posted sales growth.

But the company swung to a quarterly loss due to one-time charges related to its recently closed deals. It also launched a program to cut $1.5 billion in costs by 2025, and said it would reinvest the money in drug development.

Bristol Myers said it will prioritize investment in its key drug brands and focus its resources on research and development programs that could deliver the highest returns, among other efforts.

For the first quarter, Bristol Myers said the charges that weighed it down primarily reflect its $14-billion acquisition of neuroscience drugmaker Karuna Therapeutics and collaboration agreement with SystImmune, a subsidiary of a Chinese biotech startup, to co-develop and market its experimental cancer treatment.

Bristol Myers, one of the world's largest pharmaceutical companies, swung to a net loss of $11.9 billion, or $5.89 per share, during the first quarter. That compares to net income of $2.3 billion, or $1.07 per share, for the same period a year ago.

Excluding certain items, its adjusted loss per share was $4.40 for the period.

The loss reflects a one-time $6.30 per share charge related to the recently closed deals.

Bristol Myers reported first-quarter revenue of $11.87 billion, up 5% from the year-earlier period. Its shares began Thursday down $3.61, or 7.4%, to $45.25.

• About Us
• Contact Us
• Advertise
• License Our Content
• Jobs
• Disclaimer
• Privacy Policy

Copyright 1998 - 2024 Baystreet Media Corp. All rights reserved. Nasdaq Stocks: Information delayed 15 minutes. Non-Nasdaq Stocks: Information delayed 20 minutes. Bid and Ask quotation information for NYSE and AMEX securities is only available on a real time basis. Market Data is provided by QuoteMedia. Earnings by Zacks. Analyst Ratings by Zacks

MENAFN25042024000212011056ID1108140493

COMTEX_451444620/2604/2024-04-26T03:25:10